Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb)

Lamk M. Lamki*, James L. Murray, Michael G. Rosenblum, Yehuda Z. Patt, Richard Babaian, Michael W. Unger

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


We have evaluated immunoscintigraphy in cancer patients using four111In-labelled murine monoclonal antibodies (MoAb): 96.5 (anti-P97 of melanoma), ZME-018 (anti-high molecular weight antibody of melanoma), ZCE-025 (anti-CEA for colon cancer) and PAY-276 (anti-prostatic acid phosphatase for prostatic cancer). The effect of increasing the doses of unlabelled MoAb (co-infused with 1 mg labelled MoAb) on the relative body distribution of each labelled MoAb was assessed. Localization in the liver decreased significantly in all cases, with increasing MoAb dose, except for ZME-018. Localization in other organs increased significantly as the liver activity decreased. The spleen activity, however, fell in the case of MoAb ZME-018. Blood-pool activity increased with MoAb dose in all four MoAbs. These findings correlated with the rise in the detection rate of metastases, the plasma half-life, and other pharmacokinetic parameters. However, the dose level at which this correlation occurred varied with each antibody. These data demonstrate that co-infusion of unlabelled MoAb with111In-labelled MoAb could alter the organ distribution, pharmacokinetics and tumour uptake in a favourable manner, though the degree to which this occurs depends on the antibody in question.

Original languageEnglish
Pages (from-to)553-564
Number of pages12
JournalNuclear Medicine Communications
Issue number8
Publication statusPublished - Aug 1988

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb)'. Together they form a unique fingerprint.

Cite this